Table 3 Factors associated with irAE at ICU discharge in patients receiving ICI and admitted to the ICU (n = 110 patients)
From: ICU admission for solid cancer patients treated with immune checkpoint inhibitors
Univariate analysis | Multivariate analysis with variables clinically relevant | Multivariate analysis with backward selection | ||||
|---|---|---|---|---|---|---|
Odds ratio (95% CI) | P-value | Odds ratio (95% CI) | P-value | Odds ratio (95% CI) | P-value | |
Gender: female vs. male | 1.04 (0.46–2.32) | 0.93 | 0.93 (0.34–2.53) | 0.89 | ||
Age (per year) | 1.02 (0.98–1.06) | 0.33 | 1.01 (0.99–1.10) | 0.15 | ||
CCI (per point) | 0.91 (0.79–1.06) | 0.23 | 0.94 (0.78–1.14) | 0.54 | ||
ECOG-PS | 0.005 | 0.0005 | 0.003 | |||
2–3 | 1 | 1 | 1 | |||
1 | 3.40 (1.27–8.99) | 8.43 (2.39–29.72) | 3.66 (1.33–10.03) | |||
0 | 5.35 (1.89–15.17) | 11.23 (2.87–43.97) | 6.34 (2.13–18.90) | |||
Type of cancer | 0.61 | 0.63 | ||||
Lung | 1 | 1 | ||||
Melanoma | 2.05 (0.73–5.82) | 0.67 (0.55–12.90) | ||||
Bladder | 0.41 (0.04–3.86) | 0.31 (0.01–7.14) | ||||
Kidney | 0.82 (0.07–9.48) | 2.47 (0.16–37.43) | ||||
Other | 1.10 (0.28–4.22) | 1.08 (0.187–6.17) | ||||
Metastatic vs. localized disease | 0.86 (0.33–2.26) | 0.77 | 0.65 | |||
Cancer status | 0.22 | 0.14 | ||||
Controlled | 1 | 1 | ||||
In progression | 0.44 (0.17–1.14) | 0.30 (0.08–1.15) | ||||
Not evaluated | 0.61 (0.25–1.51) | 1.22 (0.37–4.04) | ||||
Reason for ICU admission | 0.27 | 0.12 | ||||
Respiratory | 1 | 1 | ||||
Colitis | 1.02 (0.32–3.27) | 0.57 ( 0.12–2.74) | ||||
Cardiovascular | 0.11 (0.01–0.92) | 0.03 (0.003–0.043) | ||||
Metabolic | 1.63 (0.45–5.88) | 1.00 (0.17–6.02) | ||||
Neurologic | 1.36 (0.26–7.23) | 0.35 (0.03–3.69) | ||||
Line of anticancer treatment: > 2 vs. 1–2 | 1.61 (0.56–4.67) | 0.38 | 2.06 (0.46–9.20) | 0.35 | ||
History of immune toxicity: yes vs. no | 2.61 (1.04–6.59) | 0.04 | 4.13 (0.88–19.50) | 0.07 | 3.28 (1.19–9.01) | 0.02 |
Time from first ICI infusion (per month) | 1.02 (0.97–1.07) | 0.43 | 0.94 (0.87–1.01) | 0.08 | ||